Dr. Wang is currently a tenure-track faculty member of the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina and a full member of the developmental cancer therapeutics program of Hollings Cancer Center. He received his MD from Chongqing Medical University and PhD from Peking Union Medical College. Dr. Wang’s research interests consist of stem cell biology, developmental cancer therapeutics and drug discovery, with a specific emphasis on the development of innovative therapeutic strategies to target drug-resistant cancer stem cells (CSCs) for lung and breast cancer treatment. Recent work in his lab has demonstrated that targeting the c-MYC oncoprotein is a new and effective approach to depleting CSCs in triple-negative breast cancer. He has served as the Principle Investigator (PI) or co-investigator on a number of NIH-funded projects and published more than 40 peer-reviewed research articles, invited reviews and book chapters. Dr. Wang is a full member of the American Association for Cancer Research (AACR) as well as the Radiation Research Society (RRS) and has been serving on the membership committee of RRS since 2015. He also has considerable experience with grant review and served as a reviewer for various funding agencies including NIH and NASA. In addition, Dr. Wang has reviewed a multitude of manuscripts for many scientific journals including Cancer Research, Molecular Pharmaceutics, Cell Death and Disease, and Molecular Carcinogenesis.